Incyte provides update on FDA review of Ruxolitinib cream (Opzelura®)
June 20 (Reuters) - Incyte Corp INCY.O:
UPDATE ON FDA REVIEW OF RUXOLITINIB CREAM (OPZELURA®) FOR CHILDREN AGES 2-11 WITH ATOPIC DERMATITIS
INCYTE CORP - PDUFA ACTION DATE EXTENDED TO SEPTEMBER 19, 2025
INCYTE CORP - TRUE-AD3 STUDY MET PRIMARY ENDPOINT FOR OPZELURA
INCYTE CORP - SECONDARY ENDPOINT OF EASI75 IMPROVEMENT ACHIEVED AT WEEK 8
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Nvidia Shares Hit Record High, Market Cap Tops $526 Trillion, How Much Higher Can It Go Amid AI Capex Boom?

Tradingkey







